02.06.2026
The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.
SA pharma localisation faces hurdles as Trade Minister warns against foreign investor conditions that undermine domestic procurement.